]

Research Papers

This database includes peer-reviewed publications authored by TB Alliance staff. Use the tags on the left to filter by subject, or search for a particular author or term using the search bar.

Tag: Drug Targets

Displaying 13 papers

Tuberculosis drug discovery and emerging targets

Publication: Mdluli K, Kaneko T, Upton A. Tuberculosis drug discovery and emerging targets. Ann N Y Acad Sci. 2014 Sep;1323:56-75. doi: 10.1111/nyas.12459.

6/2014

Tags: Advocacy, Drug Discovery, Drug Targets, Editorials, Preclinical Models

Identification of a small molecule with activity against drug-resistant and persistent tuberculosis

Publication: Wang F, Sambandan D, Halder R, et. al. Identification of a small molecule with activity against drug-resistant and persistent tuberculosis. Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):E2510-7. doi: 10.1073/pnas.1309171110.

5/2013

Tags: Drug Discovery, Drug Targets, MDR-TB, Preclinical Models

Strategies and challenges involved in the discovery of new chemical entities during early-stage tuberculosis drug discovery

Publication: Coxon GD, Cooper CB, Gillespie SH, McHugh TD. Strategies and challenges involved in the discovery of new chemical entities during early-stage tuberculosis drug discovery. J Infect Dis. 2012 May 15;205 Suppl 2:S258-64. doi: 10.1093/infdis/jis191.

3/2012

Tags: Advocacy, Drug Discovery, Drug Targets, Editorials

Structural insight into serine protease Rv3671c that Protects M. tuberculosis from oxidative and acidic stress

Publication: Biswas T, Small J, Vandal O, et. al. Structural insight into serine protease Rv3671c that protects M. tuberculosis from oxidative and acidic stress. Structure. 2010 Oct 13;18(10):1353-63. doi: 10.1016/j.str.2010.06.017.

10/2011

Tags: Drug Discovery, Drug Targets, M.tb. Biology

Development of a population pharmacokinetic model for taranabant, a cannibinoid-1 receptor inverse agonist

Publication: Li X (Susie), Nielsen J, Cirincione B, et. al. Development of a Population Pharmacokinetic Model for Taranabant, a Cannibinoid-1 Receptor Inverse Agonist. The AAPS Journal. 2010;12(4):537-547. doi:10.1208/s12248-010-9212-2.

6/2010

Tags: Clinical Trial Results, Drug Discovery, Drug Targets, Pharmacokinetics, Preclinical Models

Potent biphenyl- and 3-phenyl pyridine-based inhibitors of acetyl-CoA carboxylase

Publication: Haque TS, Liang N, Golla R, et. al. Potent biphenyl- and 3-phenyl pyridine-based inhibitors of acetyl-CoA carboxylase. Bioorg Med Chem Lett. 2009 Oct 15;19(20):5872-6. doi: 10.1016/j.bmcl.2009.08.077.

10/2009

Tags: Drug Discovery, Drug Targets, Preclinical Data

Acid Resistance in Mycobacterium tuberculosis

Publication: Vandal OH, Nathan CF, Ehrt S. Acid resistance in Mycobacterium tuberculosis. J Bacteriol. 2009 Aug;191(15):4714-21. doi: 10.1128/JB.00305-09.

5/2009

Tags: Advocacy, Drug Discovery, Drug Targets, M.tb. Biology

Acid-susceptible mutants of Mycobacterium tuberculosis share hypersusceptibility to cell wall and oxidative stress and to the host environment

Publication: Vandal OH, Roberts JA, Odaira T, Schnappinger D, Nathan CF, Ehrt S. Acid-susceptible mutants of Mycobacterium tuberculosis share hypersusceptibility to cell wall and oxidative stress and to the host environment. J Bacteriol. 2009 Jan;191(2):625-31. doi: 1

11/2008

Tags: Drug Discovery, Drug Targets, M.tb. Biology

Pyridine amides as potent and selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1

Publication: Wang H, Ruan Z, Li JJ, et. al. Pyridine amides as potent and selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3168-72. doi: 10.1016/j.bmcl.2008.

5/2008

Tags: Drug Discovery, Drug Targets, Preclinical Data

Mycobacterium tuberculosis DNA gyrase as a target for drug discovery

Publication: Mdluli K, Ma Z. Mycobacterium tuberculosis DNA gyrase as a target for drug discovery. Infect Disord Drug Targets. 2007 Jun;7(2):159-68. http://www.ingentaconnect.com/content/ben/iddt/2007/00000007/00000002/art00008?token=00521b85a26b1174e1f7b76504c48662a2

6/2007

Tags: Drug Discovery, Drug Targets, M.tb. Biology, MDR-TB, Preclinical Data

Antimycobacterium Agents

Publication: Ma Z, Ginsberg A, Spigelman M. Antimycobacterium Agents. Elsevier, Philadelphia, PA. 2007 Jan; 700-4, 719-20, 26.

1/2007

Tags: Clinical Development, Drug Discovery, Drug Targets, Global Pipeline, M.tb. Biology, MDR-TB, Moxifloxacin, Preclinical Models, Pretomanid/PA-824, Pyrazinamide, Rifapentine, TB-HIV, Trial Design

Novel targets for tuberculosis drug discovery

Publication: Mdluli K, Spigelman M. Novel targets for tuberculosis drug discovery. Curr Opin Pharmacol. 2006 Oct;6(5):459-67. http://www.sciencedirect.com/science/article/pii/S1471489206001354. Accessed March 7, 2016

10/2006

Tags: Drug Discovery, Drug Targets, M.tb. Biology

Mycobacterium tuberculosis: new tricks for an old bug

Publication: Spigelman M, Ma Z. Mycobacterium tuberculosis: new tricks for an old bug. Expert Rev Anti Infect Ther. 2004 Aug;2(4):467-9.https://www.researchgate.net/publication/8234528_Mycobacterium_tuberculosis_New_tricks_for_an_old_bug. Accessed March 7, 2016

8/2004

Tags: Advocacy, Drug Discovery, Drug Targets, Editorials, Global Pipeline, Pharmacokinetics